1. Clinical & Scientific Overview
Ropinirole Hydrochloride & Trihexyphenidyl Hydrochloride IP (TIP-MED-000415, Reference Code [11.27]-CMP145) is classified under
Neurology & Antiepileptic Medicines (Ch 11) as a Dopamine Precursor + Peripheral DOPA Decarboxylase Inhibitor & Non-Ergot D2/D3 Dopamine Agonist.
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Co-indexed per approved Author Decisions DEC-07 (7A) and DEC-12 (12A). Non-ergot D2/D3 agonist Ropinirole (CYP1A2 substrate) and central anticholinergic Trihexyphenidyl (Pacitane 2 mg) for Parkinsonian tremor.
Standard approved strengths (refer to comparative context)
3. Mechanism of Action & Pharmacodynamics
Co-indexed per approved Author Decisions DEC-07 (7A) and DEC-12 (12A). Non-ergot D2/D3 agonist Ropinirole (CYP1A2 substrate) and central anticholinergic Trihexyphenidyl (Pacitane 2 mg) for Parkinsonian tremor.
4. Therapeutic Indications & Evidence-Supported Uses
- Idiopathic Parkinson's disease (bradykinesia, rigidity, resting tremor) and primary Restless Legs Syndrome (Pramipexole 0
- 125–0
- 5 mg 2h before bedtime)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Co-indexed per approved Author Decisions DEC-07 (7A) and DEC-12 (12A). Non-ergot D2/D3 agonist Ropinirole (CYP1A2 substrate) and central anticholinergic Trihexyphenidyl (Pacitane 2 mg) for Parkinsonian tremor.
Administration & Meal Timing: Take Immediate-Release Levodopa+Carbidopa 30–45 min BEFORE meals (high-protein meals compete via large neutral amino acid transporters!). | Strict clock-timed dosing (e.g., 08:00, 12:00, 16:00, 20:00) to prevent 'wearing-off' motor freezing.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Comparative pharmacokinetic profile co-indexed under [11.27].
Renal: Reduce Pramipexole frequency if CrCl <50 mL/min (start 0.125 mg BD if CrCl 20–50; 0.125 mg OD if CrCl <20). Hepatic: Caution in severe hepatic impairment.
Renal: Reduce Pramipexole frequency if CrCl <50 mL/min (start 0.125 mg BD if CrCl 20–50; 0.125 mg OD if CrCl <20). Hepatic: Caution in severe hepatic impairment.
Renal: Reduce Pramipexole frequency if CrCl <50 mL/min (start 0.125 mg BD if CrCl 20–50; 0.125 mg OD if CrCl <20). Hepatic: Caution in severe hepatic impairment.
7. Contraindications, Precautions & High-Risk Warnings
- HYPERPYREXIA-PARKISONISM SYNDROME ON ABRUPT WITHDRAWAL & SUDDEN SLEEP ATTACKS: Abrupt cessation precipitates fatal Neuroleptic Malignant-like Syndrome (rigid hyperthermia, rhabdomyolysis). Pramipexole causes sudden daytime sleep attacks and impulse-control disorders (pathological gambling/bingeing).
Key Clinical Precautions: Renal: Reduce Pramipexole frequency if CrCl <50 mL/min (start 0.125 mg BD if CrCl 20–50; 0.125 mg OD if CrCl <20). Hepatic: Caution in severe hepatic impairment.
8. Adverse Effects Profile
- Nausea, orthostatic hypotension, peak-dose choreiform dyskinesias, 'wearing-off' motor fluctuations, vivid dreams/hallucinations, reddish-brown discolouration of urine/sweat/saliva (harmless).
- Parkinsonism-hyperpyrexia crisis (abrupt withdrawal), sudden onset of sleep while driving, impulse-control disorder, visual hallucinations, melanoma risk.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- STRICTLY AVOID Typical/Atypical D2 Antipsychotics (Haloperidol, Risperidone, Olanzapine) and Metoclopramide/Prochlorperazine (block striatal D2 receptors & worsen Parkinsonism! Use Domperidone for nausea or Quetiapine/Clozapine for psychosis)
- Separate oral Iron by >=2 hours (chelates Levodopa!)
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical parameters per parent class monograph [11.27].
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Take doses at the exact prescribed minute every day; separate Iron tablets by 2 hours; harmless dark urine/sweat may occur; never use Metoclopramide for vomiting; never stop tablets suddenly.
- Meal & Clock Timing Instruction: Take Immediate-Release Levodopa+Carbidopa 30–45 min BEFORE meals (high-protein meals compete via large neutral amino acid transporters!). (Strict clock-timed dosing (e.g., 08:00, 12:00, 16:00, 20:00) to prevent 'wearing-off' motor freezing.)
- Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
- Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Yes (Levodopa + Carbidopa 100/10, 100/25, 250/25) | Compendia: NFI 7th Ed 2026 / NLEM 2022
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Levodopa + Carbidopa IR Scored Tablets: 100/10 mg (Syndopa-110), 100/25 mg (Syndopa-Plus), 250/25 mg; CR Tablets: 100/25 mg, 200/50 mg. Pramipexole IR: 0.125 mg, 0.25 mg, 0.5 mg, 1 mg; ER: 0.375 mg, 0.75 mg, 1.5 mg.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [11.15]-CMP136 Chlordiazepoxide IP — Long-Acting Lipophilic Benzodiazepine (Anticonvulsant, Anxiolytic
- [11.15]-CMP137 Flumazenil IP — Long-Acting Lipophilic Benzodiazepine (Anticonvulsant, Anxiolytic
- [11.27]-C144 Carbidopa [FDC] (with Pramipexole comparison/co-therapy) — Dopamine Precursor + Peripheral DOPA Decarboxylase Inhibitor & No
- [11.28]-C146 Topiramate — Broad-Spectrum Antiepileptics, Bipolar Mood Stabiliser & Migraine